![Frontiers | A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease | Immunology Frontiers | A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease | Immunology](https://www.frontiersin.org/files/MyHome%20Article%20Library/661622/661622_Thumb_400.jpg)
Frontiers | A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease | Immunology
![Novel Nondietary Therapies for Celiac Disease - Cellular and Molecular Gastroenterology and Hepatology Novel Nondietary Therapies for Celiac Disease - Cellular and Molecular Gastroenterology and Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0b5dfd5f-be43-47ad-acea-4b26fda08013/gr1_lrg.jpg)
Novel Nondietary Therapies for Celiac Disease - Cellular and Molecular Gastroenterology and Hepatology
![ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease | Business Wire ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease | Business Wire](https://mms.businesswire.com/media/20170222005365/en/413532/23/ImmusanT_logo.jpg)
ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease | Business Wire
![Epitope-specific immunotherapy: a vaccine for coeliac disease? - The Lancet Gastroenterology & Hepatology Epitope-specific immunotherapy: a vaccine for coeliac disease? - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b13cd7ff-9044-4ad6-a679-8cca9287eadf/gr1_lrg.jpg)
Epitope-specific immunotherapy: a vaccine for coeliac disease? - The Lancet Gastroenterology & Hepatology
![ImmusanT Publishes Positive Data from Phase 1 Trials of its Celiac Disease Drug Nexvax2 - Drug Discovery and Development ImmusanT Publishes Positive Data from Phase 1 Trials of its Celiac Disease Drug Nexvax2 - Drug Discovery and Development](https://drugdiscoverytrends.com/wp-content/uploads/2019/10/celiac-disease.jpg)
ImmusanT Publishes Positive Data from Phase 1 Trials of its Celiac Disease Drug Nexvax2 - Drug Discovery and Development
![Beyond Celiac on Twitter: "RESEARCH NEWS: Nexvax2 vaccine protects against high doses of gluten, study shows. Read more about the Nexvax2 vaccine here: https://t.co/A8eqESeLVJ #celiac #celiacresearch #Nexvax2 @ImmusanT" / Twitter Beyond Celiac on Twitter: "RESEARCH NEWS: Nexvax2 vaccine protects against high doses of gluten, study shows. Read more about the Nexvax2 vaccine here: https://t.co/A8eqESeLVJ #celiac #celiacresearch #Nexvax2 @ImmusanT" / Twitter](https://pbs.twimg.com/media/D98709sWkAUNvn6.jpg)
Beyond Celiac on Twitter: "RESEARCH NEWS: Nexvax2 vaccine protects against high doses of gluten, study shows. Read more about the Nexvax2 vaccine here: https://t.co/A8eqESeLVJ #celiac #celiacresearch #Nexvax2 @ImmusanT" / Twitter
![ImmusanT's Nexvax2 demonstrates positive outcome in Phase Ib trial to treat coeliac disease - Clinical Trials Arena ImmusanT's Nexvax2 demonstrates positive outcome in Phase Ib trial to treat coeliac disease - Clinical Trials Arena](https://www.drugdevelopment-technology.com/wp-content/uploads/image-digitalinsightresearch/Active/2016Q3/2.NRI/Drug%20development/News/Core%20News/February_17/677px-Coeliac_path.jpg)
ImmusanT's Nexvax2 demonstrates positive outcome in Phase Ib trial to treat coeliac disease - Clinical Trials Arena
![A Participant's Perspective on the Failure of the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com A Participant's Perspective on the Failure of the Nexvax2 "Celiac Disease Vaccine" Clinical Trial - Celiac.com](https://www.celiac.com/uploads/monthly_2019_03/kelly_carter.thumb.jpg.5b29b21a7cc83199fb5bacd7ab0c3cf7.jpg)